Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb 7;13(4):956.
doi: 10.3390/jcm13040956.

Sodium-Glucose Co-Transporter 2 Inhibitors: Mechanism of Action and Efficacy in Non-Diabetic Kidney Disease from Bench to Bed-Side

Aly M Abdelrahman  1 , Alaa S Awad  2 , Emaad M Abdel-Rahman  3
Affiliations
Review

Sodium-Glucose Co-Transporter 2 Inhibitors: Mechanism of Action and Efficacy in Non-Diabetic Kidney Disease from Bench to Bed-Side

Aly M Abdelrahman et al. J Clin Med. .

Abstract

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are currently available for the management of type 2 diabetes mellitus. SGLT2i acts by inhibiting renal SGLT2, thereby increasing glucosuria and lowering serum glucose. Recent trials are emerging supporting a role for SGLT2i irrespective of the diabetic status pointing towards that SGLT2i have other mechanisms of actions beyond blood sugar control. In this review, we will shed light on the role of this group of medications that act as SGLT2i in non-diabetics focusing on pre-clinical and clinical data highlighting the mechanism of renoprotection and effects of SGLT2i in the non-diabetic kidneys.

Keywords: CKD; FSGS; IgAN; SGLT2i; blood pressure; non-diabetics; proteinuria; survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest with no ties to any pharmaceutical or drug-related industry.

Figures

Figure 1
Figure 1
Diabetics versus non-diabetics in metanalysis.
See this image and copyright information in PMC

References

    1. Kovesdy C.P. Epidemiology of chronic kidney disease: An update 2022. Kidney Int. Suppl. 2022;12:7–11. doi: 10.1016/j.kisu.2021.11.003. - DOI - PMC - PubMed
    1. [(accessed on 23 December 2023)]; Available online: https://usrds-adr.niddk.nih.gov/2022/end-stage-renal-disease/1-incidence....
    1. Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu. Rev. Med. 2015;66:255–270. doi: 10.1146/annurev-med-051013-110046. - DOI - PubMed
    1. Baker W.L., Buckley L.F., Kelly M.S., Bucheit J.D., Parod E.D., Brown R., Carbone S., Abbate A., Dixon D.L. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis. J. Am. Heart Assoc. 2017;6:e005686. doi: 10.1161/JAHA.117.005686. - DOI - PMC - PubMed
    1. Perkovic V., Jardine M.J., Neal B., Bompoint S., Heerspink H.J.L., Charytan D.M., Edwards R., Agarwal R., Bakris G., Bull S., et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N. Engl. J. Med. 2019;380:2295–2306. doi: 10.1056/NEJMoa1811744. - DOI - PubMed

LinkOut - more resources